Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eganelisib in AML and HR-MDS
NCT06533761Phase 1Recruiting
- Sponsor
- Stelexis Therapeutics
- Start
- Apr 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, open-label trial of eganelisib in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (4 arms), sponsored by Stelexis Therapeutics. Primary endpoints: Adverse Events at 12 months and Dose-Limiting Toxicities. Started Apr 2025; status: recruiting.
02
Drugs
eganelisib
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT06533761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06533761.